Diagnoptics News

DiagnOptics and PATH partner on project on diabetes screening in India

Groningen, the Netherlands – February 6, 2012
DiagnOptics and PATH partner on a clinical study in which the performance of point-of-care technologies for diabetes screenings will be tested in India. DiagnOptics’ recently launched Diab-spot will be tested and further developed in this clinical study in India.

There is a strong need to evaluate point-of-care (POC) technologies for diabetes screening in Indian settings and compare their performance with existing technologies. Through this study, the investigators will explore whether a testing model can guide disease treatment and management without the routine use of laboratory measurements. This study focuses on technologies that measure advanced glycation endproducts (AGEs) (such as the AGE Reader and Diab-spot) and glycemic control by POC glycated hemoglobin (HbA1c) readers.

Diab-spot offers a noninvasive and convenient method for diabetes screening with an immediate screening result on the spot. “DiagnOptics is convinced that Diab-spot can make a difference in the mission to find undiagnosed diabetics,” says DiagnOptics managing director, Bart van den Berg.

The principal investigator of this research project is Dr. Bernhard H. Weigl from the United States collaborator, PATH.  The study is funded under PATH’s Center for POC Diagnostics for Global Health, which is supported by National Institutes of Health/National Institute of Biomedical Imaging and Bioengineering (NIBIB). The Indian principal investigator is Dr. V.Mohan from the Madras Diabetes Research Foundation (MDRF) Chennai, India. PATH and MDRF hope that results from this study will provide the basis for larger programmatic activities to use and benefit from the novel low-cost technical approaches in the areas of diabetes screening and control in India.

Latest news items